KNSA News and Press, Kiniksa Pharmaceuticals Ltd. From 05/02/23

2023-05-02 12:40:33 ET Kiniksa Pharmaceuticals ( NASDAQ: KNSA ) rose ~14% on Tuesday after the Bermuda-headquartered biotech reported better-than-expected Q1 2023 financials and increased its full-year guidance for its main revenue generator Arcalyst pericarditis therapy. Ki...

2023-05-02 10:02:29 ET Gainers: TScan Therapeutics ( TCRX ) +17% . Vivani Medical ( VANI ) +15% . SI-BONE ( SIBN ) +13% . Kiniksa Pharmaceuticals ( KNSA ) +12% . Harmony Biosciences ( HRMY ) +8% . Losers: Community Health ...

2023-05-02 08:30:27 ET Kiniksa Pharmaceuticals press release ( NASDAQ: KNSA ): Q1 GAAP EPS of -$0.18. Revenue of $48.3M (+50.0% Y/Y). Net loss for the first quarter of 2023 was $12.3 million, compared to a net loss of $25.2 million for the first quarter of 2022. As...

– ARCALYST ® (rilonacept) Q1 2023 net product revenue of $42.7 million – – ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint – – Final cohor...

HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time to report its first quarter 2023 financial results and recent portfolio exec...

2023-04-05 13:40:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise produ...

The following slide deck was published by Kiniksa Pharmaceuticals, Ltd. in conjunction with their 2022 Q4 earnings call. For further details see: Kiniksa Pharmaceuticals, Ltd. 2022 Q4 - Results - Earnings Call Presentation

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 2022 Results Conference Call February 28, 2023 08:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial...

Kiniksa Pharmaceuticals press release ( NASDAQ: KNSA ): Q4 GAAP EPS of $0.06. Revenue of $61.88M (+230.9% Y/Y). Shares +1.8% PM. For further details see: Kiniksa Pharmaceuticals GAAP EPS of $0.06, revenue of $61.88M

– ARCALYST ® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively – – ARCALYST full-year 2023 net product revenue expected to be $190 - $205 million, representing >60% year-over-year growth...